HiberCell, a New York City biotech startup, started operations with $60.75 million in Series A funding led by ARCH Venture Partners, and joined by China investors, Hillhouse Capital and 6 Dimensions Capital. HiberCell is focused on developing treatments that prevent cancer relapse and metastasis by focusing on detecting and treating dormant disseminated tumor cells. As HiberCell points out, most cancer deaths are caused by metastases, which can occur even if the primary cancer has been treated successfully. More details....
Share this with colleagues: